

Press release for immediate release

## Genomtec signs distribution agreement for Genomtec®ID in Europe

Wroclaw, Poland - April 29, 2022. - Genomtec S.A. "GMT", a NewConnect-listed MedTech company specializing in the development of mobile point-of-care (POC) genetic diagnostics technology, has signed an exclusive distribution agreement in Greece for its flagship Genomtec®ID genetic testing platform and the Respiratory Panel 5-plex test. Genomtec's commercial partner Atropos Ltd., is a specialist distributor of molecular biology solutions with an established market position in Greece. Atropos will start the distribution following the regulatory approval of the Genomtec®ID platform and the test. Atropos has committed to a minimum order for both the analyzer and reaction cards for the rapid diagnosis of respiratory infections with a total value of €350,000 over a 3-year period. Genomtec plans to register the Genomtec®ID in the middle of this year.

*- This is exciting news for us, our investors, patients and healthcare managers. We are in the process of clinical trials with the use of our Genomtec®ID platform, which we intend to register in the European Union in the middle of this year. This distribution agreement confirms that our idea, which our entire team has been working hard on for almost six years, has attracted market interest and is poised to empower physicians with technology that can improve patient outcomes. With Genomtec®ID we will augment the genetic laboratory to doctor's offices, hospital emergency rooms or ambulances and the speed of test results obtained in this way will give patients a chance for a quick and precise diagnosis during a single meeting - said Charudutt Shah, Chief Business Officer in Genomtec.*

ATROPOS Ltd, has been present on the market of in-vitro diagnostics and food quality control for 30 years and considers public health and consumer safety as its most important values. Thanks to its success, Atropos has established itself as a reliable provider of high-quality, innovative diagnostic solutions and financial stability.

The first disease panel that Genomtec®ID will detect is a respiratory panel, which continues to be an important need in the current period with continuation of COVID-19 disease. The panel will test for infection with one of five pathogens in a single test including: SARS-Cov-2, Influenza A/B, Respiratory Syncytial Virus (RSV), *Mycoplasma pneumoniae* and *Chlamydia pneumoniae*.

#####

### Additional information at:

Genomtec S.A.  
Magdalena Kicińska  
+48 604 201 230  
[m.kicinska@genomtec.com](mailto:m.kicinska@genomtec.com)

### About Genomtec:



Genomtec is an innovative medical technology company dedicated to the development and commercialization of a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.

The company's flagship project is the Genomtec ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent protected SNAAT® isothermal technology. Appropriate design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies. According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution will take place in the first half of 2022.

Manufacturing of Genomtec® SARS-CoV-2 EvaGreen® laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe.

Genomtec was founded in 2016.

Genomtec SA is headquartered in Wrocław.

More information at: [www.genomtec.com](http://www.genomtec.com)

#### **About LabRaum:**

**[Insert Company Description]**

More information at: [www.labraum.at](http://www.labraum.at)